Resistance to integrase inhibitors

Viruses

Volumn 2, Issue 7, 2010, Pages 1347-1366

  Métifiot, Mathieu ^a   Marchand, Christophe ^a   Maddali, Kasthuraiah ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Elvitegravir; GSK 1265744; GSK 1349572; HIV 1 integrase; Interfacial inhibitors; Raltegravir; Resistance

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 5 CITEP; CAPE; DIKETO ACID; DIKETO ACID DERIVATIVE; ELVITEGRAVIR; GS 1937; GSK 1265744; GSK 1349572; INTEGRASE; INTEGRASE INHIBITOR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; RALTEGRAVIR; S GSK 1349572; UNCLASSIFIED DRUG; V 165; ZINTEVIR;

ANTIVIRAL RESISTANCE; CROSS RESISTANCE; DRUG ACTIVITY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; TREATMENT FAILURE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77958015399     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2071347     Document Type: Review

References (100)

1. Delelis, O.; Carayon, K.; Saib, A.; Deprez, E.; Mouscadet, J.F. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008, 5, 114.
2. Nishitsuji, H.; Hayashi, T.; Takahashi, T.; Miyano, M.; Kannagi, M.; Masuda, T. Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection. PLoS One 2009, 4, e7825.
3. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug. Discov. 2005, 4, 236-248.
4. Jaskolski, M.; Alexandratos, J.N.; Bujacz, G.; Wlodawer, A. Piecing together the structure of retroviral integrase, an important target in AIDS therapy. FEBS J. 2009, 276, 2926-2946.
5. Chiu, T.K.; Davies, D.R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 2004, 4, 965-977.
6. Faure, A.; Calmels, C.; Desjobert, C.; Castroviejo, M.; Caumont-Sarcos, A.; Tarrago-Litvak, L.; Litvak, S.; Parissi, V. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 2005, 33, 977-986.
7. Van Maele, B.; Debyser, Z. HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev. 2005, 7, 26-43.
8. Van Maele, B.; Busschots, K.; Vandekerckhove, L.; Christ, F.; Debyser, Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci. 2006, 31, 98-105.
9. Riviere, L.; Darlix, J.L.; Cimarelli, A. Analysis of the viral elements required in the nuclear import of HIV-1 DNA. J. Virol. 2010, 84, 729-739.
10. Ferris, A.L.; Wu, X.; Hughes, C.M.; Stewart, C.; Smith, S.J.; Milne, T.A.; Wang, G.G.; Shun, M.C.; Allis, C.D.; Engelman, A.; Hughes, S.H. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 3135-3140.
11. Engelman, A.; Cherepanov, P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008, 4, e1000046.
12. Craigie, R. Targeting HIV-1 DNA integration by swapping tethers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 2735-2736.
13. Craigie, R.; Mizuuchi, K.; Bushman, F.D.; Engelman, A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 1991, 19, 2729-2734.
14. Fesen, M.R.; Kohn, K.W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 2399-2403.
15. Goodarzi, G.; Im, G.J.; Brackmann, K.; Grandgenett, D. Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase. J. Virol. 1995, 69, 6090-6097.
16. Nowotny, M. Retroviral integrase superfamily: the structural perspective. EMBO Rep. 2009, 10, 144-151.
17. Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Engelman, A.; Craigie, R.; Davies, D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
18. Greenwald, J.; Le, V.; Butler, S.L.; Bushman, F.D.; Choe, S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38, 8892-8898.
19. Maignan, S.; Guilloteau, J.P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
20. Chen, J.C.; Krucinski, J.; Miercke, L.J.; Finer-Moore, J.S.; Tang, A.H.; Leavitt, A.D.; Stroud, R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 8233-8238.
21. Wang, J.Y.; Ling, H.; Yang, W.; Craigie, R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333-7343.
22. Ren, G.; Gao, K.; Bushman, F.D.; Yeager, M. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J. Mol. Biol. 2007, 366, 286-294.
23. Wielens, J.; Crosby, I.T.; Chalmers, D.K. A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput. Aided Mol. Des. 2005, 19, 301-317.
24. Cherepanov, P.; Ambrosio, A.L.; Rahman, S.; Ellenberger, T.; Engelman, A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 17308-17313.
25. Fitzkee, N.C.; Masse, J.E.; Shen, Y.; Davies, D.R.; Bax, A. Solution conformation and dynamics of the HIV-1 integrase core domain. J. Biol. Chem. 2010, 285, 18072-18084.
26. Chen, A.; Weber, I.T.; Harrison, R.W.; Leis, J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J. Biol. Chem. 2006, 281, 4173-4182.
27. Johnson, A.A.; Santos, W.; Pais, G.C.; Marchand, C.; Amin, R.; Burke, T.R., Jr.; Verdine, G.; Pommier, Y. Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J. Biol. Chem. 2006, 281, 461-467.
28. Lu, R.; Limon, A.; Ghory, H.Z.; Engelman, A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J. Virol. 2005, 79, 2493-2505.
29. Marinello, J.; Marchand, C.; Mott, B.T.; Bain, A.; Thomas, C.J.; Pommier, Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008, 47, 9345-9354.
30. Esposito, D.; Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 1998, 17, 5832-5843.
31. Acevedo, M.L.; Arbildua, J.J.; Monasterio, O.; Toledo, H.; Leon, O. Role of the 207-218 peptide region of Moloney murine leukemia virus integrase in enzyme catalysis. Arch. Biochem. Biophys. 2010, 495, 28-34.
32. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 167-168.
33. Valkov, E.; Gupta, S.S.; Hare, S.; Helander, A.; Roversi, P.; McClure, M.; Cherepanov, P. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 2009, 37, 243-255.
34. Marchand, C.; Maddali, K.; Métifiot, M.; Pommier, Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 2009, 9, 1016-1037.
35. Ramkumar, K.; Serrao, E.; Odde, S.; Neamati, N. HIV-1 integrase inhibitors: 2007-2008 update. Med. Res. Rev. 2010, In press.
36. Liao, C.; Marchand, C.; Burke, T.R.; Pommier, Y.; Nicklaus, M.C. Authentic HIV-1 Integrase Inhibitors. Future Med. Chem. 2010, In press.
37. Robinson, W.E. Jr.; Reinecke, M.G.; Abdel-Malek, S.; Jia, Q.; Chow, S.A. Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 6326-6331.
38. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
39. Andreola, M.L. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase. Curr. Pharm. Des. 2009, 15, 2508-2519.
40. Jing, N.; Xu, X. Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr. Drug. Targets Infect. Disord. 2001, 1, 79-90.
41. Ojwang, J.O.; Buckheit, R.W.; Pommier, Y.; Mazumder, A.; De Vreese, K.; Este, J.A.; Reymen, D.; Pallansch, L.A.; Lackman-Smith, C.; Wallace, T.L.; et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1995, 39, 2426-2435.
42. Jing, N.; Marchand, C.; Guan, Y.; Liu, J.; Pallansch, L.; Lackman-Smith, C.; De Clercq, E.; Pommier, Y. Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides. DNA Cell Biol. 2001, 20, 499-508.
43. Cherepanov, P.; Este, J.A.; Rando, R.F.; Ojwang, J.O.; Reekmans, G.; Steinfeld, R.; David, G.; De Clercq, E.; Debyser, Z. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 1997, 52, 771-780.
44. Este, J.A.; Cabrera, C.; Schols, D.; Cherepanov, P.; Gutierrez, A.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; Rando, R.F.; Clotet, B.; Desmyter, J.; De Clercq, E. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 1998, 53, 340-345.
45. Semenova, E.A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: update and perspectives. Adv. Pharmacol. 2008, 56, 199-228.
46. Grobler, J.A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.S.; Young, S.; Vacca, J.; Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 6661-6666.
47. Serrao, E.; Odde, S.; Ramkumar, K.; Neamati, N. Raltegravir, elvitegravir, and metoogravir: the birth of me-too HIV-1 integrase inhibitors. Retrovirology 2009, 6, 25.
48. Correll, T.; Klibanov, O.M. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008, 28, 90-101.
49. Singh, I.R.; Gorzynski, J.E.; Drobysheva, D.; Bassit, L.; Schinazi, R.F. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 2010, 5, e9948.
50. Vandeckerckhove, L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr. Opin. Investig. Drugs 2010, 11, 203-212.
51. Pommier, Y.; Cherfils, J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol. Sci. 2005, 28, 136-145.
52. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009, 24, 106-107.
53. Cocohoba, J. The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals. Expert Rev. Anti. Infect. Ther. 2009, 7, 1159-1163.
54. Emery, S.; Winston, A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009, 374, 764-766.
55. Garrido, C.; Soriano, V.; de Mendoza, C. New therapeutic strategies for raltegravir. J. Antimicrob. Chemother. 2010, 65, 218-223.
56. Lennox, J.L.; DeJesus, E.; Lazzarin, A.; Pollard, R.B.; Madruga, J.V.; Berger, D.S.; Zhao, J.; Xu, X.; Williams-Diaz, A.; Rodgers, A.J.; Barnard, R.J.; Miller, M.D.; DiNubile, M.J.; Nguyen, B.Y.; Leavitt, R.; Sklar, P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374, 796-806.
57. Markowitz, M.; Nguyen, B.Y.; Gotuzzo, E.; Mendo, F.; Ratanasuwan, W.; Kovacs, C.; Prada, G.; Morales-Ramirez, J.O.; Crumpacker, C.S.; Isaacs, R.D.; Gilde, L.R.; Wan, H.; Miller, M.D.; Wenning, L.A.; Teppler, H. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 2007, 46, 125-133.
58. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; Dornadula, G.; Danovich, R.M.; Witmer, M.V.; Wilson, K.A.; Tussey, L.; Schleif, W.A.; Gabryelski, L.S.; Jin, L.; Miller,M.D.; Casimiro, D.R.; Emini, E.A.; Shiver, J.W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
59. Fransen, S.; Gupta, S.; Danovich, R.; Hazuda, D.; Miller, M.; Witmer, M.; Petropoulos, C.J.; Huang, W. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 2009, 83, 11440-11446.
60. Cooper, D.A.; Steigbigel, R.T.; Gatell, J.M.; Rockstroh, J.K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P.N.; Eron, J.E.; Schechter, M.; Markowitz, M.; Loutfy, M.R.; Lennox, J.L.; Zhao, J.; Chen, J.; Ryan, D.M.; Rhodes, R.R.; Killar, J.A.; Gilde, L.R.; Strohmaier, K.M.; Meibohm, A.R.; Miller, M.D.; Hazuda, D.J.; Nessly, M.L.; DiNubile, M.J.; Isaacs, R.D.; Teppler H.; Nguyen, B.Y. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359, 355-365.
61. Delelis, O.; Malet, I.; Na, L.; Tchertanov, L.; Calvez, V.; Marcelin, A.G.; Subra, F.; Deprez, E.; Mouscadet, J.F. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009, 37, 1193-1201.
62. Delelis, O.; Thierry, S.; Subra, F.; Simon, F.; Malet, I.; Alloui, C.; Sayon, S.; Calvez, V.; Deprez, E.; Marcelin, A.G.; Tchertanov, L.; Mouscadet, J.F. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 2010, 54, 491-501.
63. Tsurutani, N.; Kubo, M.; Maeda, Y.; Ohashi, T.; Yamamoto, N.; Kannagi, M.; Masuda, T. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J. Virol. 2000, 74, 4795-4806.
64. Low, A.; Prada, N.; Topper, M.; Vaida, F.; Castor, D.; Mohri, H.; Hazuda, D.; Muesing, M.; Markowitz, M. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob. Agents Chemother. 2009, 53, 4275-4282.
65. Loizidou, E.Z.; Kousiappa, I.; Zeinalipour-Yazdi, C.D.; Van de Vijver, D.A.; Kostrikis, L.G. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry 2009, 48, 4-6.
66. Malet, I.; Delelis, O.; Valantin, M.A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J.F.; Katlama, C.; Calvez, V.; Marcelin, A.G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52, 1351-1358.
67. Ceccherini-Silberstein, F.; Malet, I.; D'Arrigo, R.; Antinori, A.; Marcelin, A.G.; Perno, C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11, 17-29.
68. Sichtig, N.; Sierra, S.; Kaiser, R.; Daumer, M.; Reuter, S.; Schulter, E.; Altmann, A.; Fatkenheuer, G.; Dittmer, U.; Pfister, H.; Esser, S. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother. 2009, 64, 25-32.
69. Charpentier, C.; Laureillard, D.; Piketty, C.; Tisserand, P.; Batisse, D.; Karmochkine, M.; Si-Mohamed, A.; Weiss, L. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010, 24, 867-873.
70. Quercia, R.; Dam, E.; Perez-Bercoff, D.; Clavel, F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J. Virol. 2009, 83, 10245-10249.
71. Métifiot, M.; Maddali, K.; Naumova, A.; Zhang, X.; Marchand, C.; Pommier, Y. Biochemical and Pharmacological Analyses of HIV-1 Integrase Flexible Loop Mutants Resistant to Raltegravir. Biochemistry 2010, 49, 3715-3722.
72. Fransen, S.; Karmochkine, M.; Huang, W.; Weiss, L.; Petropoulos, C.; Charpentier, C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV-1 during virologic failure. Antimicrob. Agents Chemother. 2009, 53, 4522-4524.
73. da Silva, D.; Van Wesenbeeck, L.; Breilh, D.; Reigadas, S.; Anies, G.; Van Baelen, K.; Morlat, P.; Neau, D.; Dupon, M.; Wittkop, L.; Fleury, H.; Masquelier, B. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J. Antimicrob. Chemother. 2010, 65, 1262-1269.
74. Zolopa, A.R.; Berger, D.S.; Lampiris, H.; Zhong, L.; Chuck, S.L.; Enejosa, J.V.; Kearney, B.P.; Cheng, A.K. Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial. J. Infect. Dis. 2010, 201, 814-822.
75. DeJesus, E.; Berger, D.; Markowitz, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion R.; Farthing, C.; Zhong, L.; Cheng, A.K.; McColl, D.; Kearney, B.P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 2006, 43, 1-5.
76. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82, 764-774.
77. Gerton, J.L.; Ohgi, S.; Olsen, M.; DeRisi, J.; Brown, P.O. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J. Virol. 1998, 72, 5046-5055.
78. Charpentier, C.; Karmochkine, M.; Laureillard, D.; Tisserand, P.; Bélec, L.; Weiss, L.; Si-Mohamed, A.; Piketty, C. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 2008, 9, 765-770.
79. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development. Presented at the 9th Conference on Retrovirures and Opportunistic Infections, Seattle, WA, USA, 2002.
80. Fikkert, V.; Van Maele, B.; Vercammen, J.; Hantson, A.; Van Remoortel, B.; Michiels, M.; Gurnari, C.; Pannecouque, C.; De Maeyer, M.; Engelborghs, Y.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 2003, 77, 11459-11470.
81. Svarovskaia, E.S.; Barr, R.; Zhang, X.; Pais, G.C.; Marchand, C.; Pommier, Y.; Burke, T.R.; Jr.; Pathak, V.K. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 2004, 78, 3210-3222.
82. Lee, D.J.; Robinson, W.E., Jr. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. J. Virol. 2004, 78, 5835-5847.
83. Hazuda, D.J.; Anthony, N.J.; Gomez, R.P.; Jolly, S.M.; Wai, J.S.; Zhuang, L.; Fisher, T.E.; Embrey, M.; Guare, J.P. Jr.; Egbertson, M.S.; Vacca, J.P.; Huff, J.R.; Felock, P.J.; Witmer, M.V.; Stillmock, K.A.; Danovich, R.; Grobler, J.; Miller, M.D.; Espeseth, A.S.; Jin, L.; Chen, I.W.; Lin, J.H.; Kassahun, K.; Ellis, J.D.; Wong, B.K.; Xu, W.; Pearson, P.G.; Schleif, W.A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M.K.; Young, S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 11233-11238.
84. Fikkert, V.; Hombrouck, A.; Van Remoortel, B.; De Maeyer, M.; Pannecouque, C.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. Aids 2004, 18, 2019-2028.
85. Goethals, O.; Clayton, R.; Van Ginderen, M.; Vereycken, I.; Wagemans, E.; Geluykens, P.; Dockx, K.; Strijbos, R.; Smits, V.; Vos, A.; Meersseman, G.; Jochmans, D.; Vermeire, K.; Schols, D.; Hallenberger, S.; Hertogs, K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82, 10366-10374.
86. Dicker, I.B.; Terry, B.; Lin, Z.; Li, Z.; Bollini, S.; Samanta, H.K.; Gali, V.; Walker, M.A.; Krystal, M.R. Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer Inhibitors. J. Biol. Chem. 2008, 283, 23599-23609.
87. Kobayashi, M.; Nakahara, K.; Seki, T.; Miki, S.; Kawauchi, S.; Suyama, A.; Wakasa-Morimoto, C.; Kodama, M.; Endoh, T.; Oosugi, E.; Matsushita, Y.; Murai, H.; Fujishita, T.; Yoshinaga, T.; Garvey, E.; Foster, S.; Underwood, M.; Johns, B.; Sato, A.; Fujiwara, T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008, 80, 213-222.
88. Hombrouck, A.; Voet, A.; Van Remoortel, B.; Desadeleer, C.; De Maeyer, M.; Debyser, Z.; Witvrouw, M. Mutations in HIV-1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross Resistance to the Clinical Trial drug GS-9137. Antimicrob. Agents Chemother. 2008, 52, 2069-2078.
89. Buzón, M.; Dalmau, J.; Puertas, M.; Puig, J.; Clotet, B.; Martinez-Picado, J. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. Aids 2009, 24, 17-25.
90. Nakahara, K.; Wakasa-Morimoto, C.; Kobayashi, M.; Miki, S.; Noshi, T.; Seki, T.; Kanamori-Koyama, M.; Kawauchi, S.; Suyama, A.; Fujishita, T.; Yoshinaga, T.; Garvey, E.; Johns, B.; Foster, S.; Underwood, M.; Sato, A.; Fujiwara, T. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2008, 81, 141-146.
91. King, P.J.; Lee, D.J.; Reinke, R.A.; Victoria, J.G.; Beale, K.; Robinson, W.E., Jr. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 2003, 306, 147-161.
92. King, P.J.; Robinson, W.E., Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 1998, 72, 8420-8424.
93. Baldanti, F.; Paolucci, S.; Gulminetti, R.; Brandolini, M.; Barbarini, G.; Maserati, R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J. Med. Virol. 2009, 82, 116-122.
94. Malet, I.; Delelis, O.; Soulie, C.; Wirden, M.; Tchertanov, L.; Mottaz, P.; Peytavin, G.; Katlama, C.; Mouscadet, J.F.; Calvez, V.; Marcelin, A.G. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 2009, 63, 795-804.
95. Ferns, R.B.; Kirk, S.; Bennett, J.; Williams, I.; Edwards, S.; Pillay, D. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009, 23, 2159-2164.
96. Canducci, F.; Marinozzi, M.C.; Sampaolo, M.; Boeri, E.; Spagnuolo, V.; Gianotti, N.; Castagna, A.; Paolucci, S.; Baldanti, F.; Lazzarin, A.; Clementi, M. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J. Antimicrob. Chemother. 2010, 65, 425-433.
97. Dicker, I.B.; Samanta, H.K.; Li, Z.; Hong, Y.; Tian, Y.; Banville, J.; Remillard, R.R.; Walker M.A.; Langley D.R.; Krystal M. Changes to the HIV LTR and to HIV integrase differentially impact HIV integrase assembly, activity and the binding of strand transfer inhibitors. J. Biol. Chem. 2007, 282, 31186-31196.
98. Zahm, J.A.; Bera, S.; Pandey, K.K.; Vora, A.; Stillmock, K.; Hazuda, D.; Grandgenett, D.P. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob. Agents Chemother. 2008, 52, 3358-3368.
99. Passaes, C.B.; Guimarães, M.L.; Fernandez, S.L.C.; Lorete, R.D.S.; Teixeira, S.L.M.; Fernandez, J.C.C.; Morgado, M.G. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J. Acquir. Immune Defic. Syndr. 2009, 51, 7-12.
100. Yeh, R.F.; Jain, R.; Palmer, H.R. 49th ICAAC annual meeting: optimization of anti-infective use in the clinical setting. Expert Rev. Anti. Infect. Ther. 2009, 7, 1167-1172.